Benitec Biopharma
Hayward
About Benitec Biopharma
Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. Their transformational technology, ddRNAi, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. Compared to traditional approaches to RNA intereference, ddRNAi is easier to deliver, safer to us, more targeted and more efficient. Benitec has a pipeline of in-house and partnered drug development programs based on ddRNAI, including Hepatitis C and B, cancer-associated pain and drug-resistant lung cancer. Our Hepatitis C program is nearing clinical trials in 2013. ddRNAi has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. The technology is available from Benitec under a variety of licence options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $249.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: asx:BLT
- Website: benitec.com
- Phone: 4089602207
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/benitec-biopharma-98692 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.